The effect of itraconazole pulse therapy on quality of life in Pakistani patients of distolateral subungual onychomycosis

Authors

  • Shahbaz Aman
  • Talat M. Akbar
  • Ijaz Hussain
  • Muhammad Jahangir
  • Tahir S. Haroon

Keywords:

Onychomycosis, quality of life, itraconazole

Abstract

Background Distal and lateral subungual onychomycosis (DLSO) is the most commonclinical type of onychomycosis. The disease causes little physical handicap but it has adevastating effect on quality of life (QOL) particularly in our set up.Objective The purpose of the study was to assess the effect of itraconazole pulse therapy onquality of life in Pakistani patients with DLSO.Methods Sixty-two patients, 47 males and 15 females suffering from DLSO, age range 19 to55 years, who were themselves able to understand and fill the questionnaire related withgeneral and disease-specific QOL in English or Urdu version, were enrolled in the study. Thetotal score ranged from 0-60. The higher the score, the greater was the impact on QOL. Thepatients were subjected to itraconazole pulse therapy and each pulse consisted of 200 mgtwice a day for 7 days, followed by a drug-free interval of three weeks. Two pulses weregiven for fingernail onychomycosis and three pulses for toenail infection. The pre- and posttrialdata was analyzed before and after therapy in 46 finger- and 16 toenail cases of DLSO.Results The disease caused psychosocial problems (92%), economic problems in treatment(89.4%), difficulty in cutting nails (62.9%), physical contact problems with hands (60.8%),discomfort in wearing shoes and walking (56.2%), pain (33.8%), disturbance of work withhands (30.4%) and affected performance in sports (22.5%). After itraconazole pulse therapy,these problems decreased to 12.9%, 14.5%, 6.45%, 6.4%, 12.5%, 4.8%, 6.45% and 3.2%,respectively. The mean pretreatment score in patients with finger- and toenail disease was32+3.4 and 29+4.5, respectively. The score dropped to 4.3+5.4 and 4.4+5.6 (P<0.05) afteritraconazole therapy at last follow-up 32 weeks and 48 weeks for finger- and toenail disease,respectively. Fingernail disease has affected QOL more than toenail disease and longerduration of disease, greater involvement of individual nails and greater number of nailsinvolved was also associated with more serious impact on QOL. Females were found to bemore psychologically upset than males.Conclusion Itraconazole pulse therapy significantly improves the QOL in disto-lateralsubungual onychomycosis of both finger- and toenails in our patients.

References

Joish VN, Armstrong EP. Which

antifungal agent for

onychomycosis? A

pharmacoeconomic analysis.

Pharmacoeconomics 2001; 19:

-1002.

Andre J, Achten G.

Onychomycosis. Int J Dermatol

; 26: 481-90.

Zaias N. Onychomycosis. Dermatol

Clin 1985; 3: 445-60.

Scher RK. Onychomycosis: A

significant medical disorder. J Am

Acad Dermatol 1996; 35: S2-5.

Barranco V. New approaches to the

diagnosis and management of

onychomycosis. Int J Dermatol

; 33: 292-9.

Richard B, Odom R. New therapies

for onychomycosis. J Am Acad

Dermatol 1996; 35: S26-30.

Doward LC, McKenna SP.

Evolution of quality of life

assessment. In: Rajagopalan R,

Sheretz EF, Anderson TR, eds.

Care Management of Skin

Diseases. New York: Marcell

Dekker 1998: 9-94.

Lubeck DP, Gause D, Schein JR et

al. A health-related quality of life

measure for use in patients with

onychomycosis: A validation study.

Qual Life Res 1999; 8: 121-9.

Lubeck DP, Patrick DL, McNulty P

et al. Quality of life of persons with

onychomycosis. Qual Life Res

; 2: 341-8.

Shaw JW, Joish VN, Coons SJ.

Onychomycosis: health-related

quality of life considerations.

Pharmacoeconomics 2002; 20: 23-

Elewski BE. Onychomycosis:

Treatment, quality of life and economic issues. Am J Clin

Dermatol 2000; 1: 19-26.

Millikan LE, Powell DW, Drake

LA. Quality of life for patients with

onychomycosis. Int J Dermatol

; 38 (Suppl. 2): 13-6.

Lubeck DP. Measuring healthrelated

quality of life in

onychomycosis. J Am Acad

Dermatol 1998; 38: S64-68.

Turner RR, Testa MA. Measuring

the impact of onychomycosis on

patient quality of life. Qual Life Res

; 9: 39-53.

Stier DM, Gause D, Joseph WS et

al. Patients satisfaction with oral

versus nonoral therapeutic

approaches in onychomycosis. J

Am Podiatr Med Assoc 2001; 91:

-7.

Scher RK. Onychomycosis is more

than a cosmetic problem. Br J

Dermatol 1994; 130 (Suppl. 43):

Drake LA, Scher RK, Smith EB et

al. Effect of onychomycosis on

quality of life. J Am Acad Dermatol

; 38: 702-4.

Downloads

Published

2017-01-03

Issue

Section

Original Articles

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>